Pavel Orr

Persistence carries the most weight when tissue, cell composition, and technical conditions are comparable, since uncontrolled context can produce an apparent transcript change.

Agreed. The family comparison can filter recurrent transcript outliers, but the evidentiary step is allele linkage. Read-backed RNA phase can connect an aberrant isoform to a heterozygous site when both are covered, yet DNA confirmation remains necessary because expression, nonsense-mediated decay, mapping bias, and low allelic depth can obscure the inherited allele. Were parental DNA genotypes confirmed with an assay sensitive to mosaicism, and was phase supported by multiple informative reads rather than a single transcript molecule?

Keep the two discordant observations separate. The older unaffected carrier is weak negative evidence only after confirming age at evaluation, examination for mild expression, and a gene and phenotype specific penetrance estimate. The affected noncarrier is a different problem: confirm the assay and biological relationship, then assess whether the relative has the same specific phenotype or a plausible phenocopy. ACMG/AMP guidance states that age dependent penetrance and phenocopies can confound apparent nonsegregation, while expert specifications for reduced penetrance disorders may exclude genotype positive, phenotype negative relatives from benign segregation evidence. Additional distant, well phenotyped relatives may be more informative than forcing either discordant individual into a decisive category. Is there a penetrance estimate for carriers at the unaffected relative's current age?

The two affected carriers provide some supporting segregation evidence, but the affected noncarrier and older unaffected carrier should remain separate observations rather than being collapsed into a simple count. Confirm phenotype specificity, testing and biological relationships first. The affected noncarrier may represent a phenocopy, locus heterogeneity, or an assay problem. The unaffected carrier is informative only relative to age, examination quality, variable expression, and the gene and phenotype specific penetrance curve. ClinGen guidance limits use of unaffected individuals when penetrance is incomplete and favors formal analysis with age specific liability classes when possible. Is there a gene and phenotype specific penetrance estimate for the unaffected carrier’s age, and are additional informative relatives available for testing?

Available family evidence is mixed: two affected carriers support segregation, while the affected noncarrier and older unaffected carrier are discordant observations. Neither should be treated as decisive until the relationships and genotypes are confirmed, phenotypes are compared using the same criteria, and age at last evaluation is documented. ACMG/AMP guidance specifically cautions that age dependent penetrance, mild expression, and phenocopies can confound apparent nonsegregation. The affected noncarrier may weigh against causality if the phenotype is highly specific and no phenocopy or locus heterogeneity is plausible. The unaffected carrier is less informative when penetrance is incomplete or onset can occur after the relative's current age. A penetrance aware likelihood model is preferable to counting relatives equally, but it needs defensible age specific estimates rather than a generic incomplete penetrance label. Is there a gene and phenotype specific penetrance estimate for someone of the unaffected carrier's age?